Amarin Corporation Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
80
- Stock Symbol
-
AMRN
- Investments
-
4
- Share Price
-
$10.55
- (As of Friday Closing)
Amarin Corporation General Information
Description
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
Contact Information
Website
www.amarincorp.comCorporate Office
- One Central Plaza
- Dame Street, Dublin 2
- Dublin D02 K7K5
- Leinster
- Ireland
Corporate Office
- One Central Plaza
- Dame Street, Dublin 2
- Dublin D02 K7K5
- Leinster
- Ireland
Amarin Corporation Stock Performance
As of 20-Nov-2026, Amarin Corporation’s stock price is $10.55. Its current market cap is $222M with 42M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.55 | $11.25 | $10.55 - $17.31 | $222M | 42M | 78.9K | -$0.80 |
Amarin Corporation Financials Summary
As of 30-Sep-2026, Amarin Corporation has a trailing 12-month revenue of $176M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (36,796) | 10,306 | (98,018) | 43,522 |
| Revenue | 176,112 | 213,646 | 228,614 | 306,911 |
| EBITDA | (24,926) | (43,866) | (87,583) | (62,560) |
| Net Income | (19,141) | (38,798) | (82,183) | (59,112) |
| Total Assets | 634,081 | 670,775 | 685,349 | 831,684 |
| Total Debt | 5,353 | 6,080 | 7,723 | 8,737 |
Amarin Corporation Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Amarin Corporation Comparisons
Industry
Financing
Details
Amarin Corporation Competitors (23)
One of Amarin Corporation’s 23 competitors is Landsteiner Scientific, a Formerly PE-Backed company based in Toluca, Mexico.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Landsteiner Scientific | Formerly PE-Backed | Toluca, Mexico | ||||
| Elite Pharmaceuticals | Corporation | Northvale, NJ | ||||
| Mayne Pharma Group | Corporation | Salisbury, Australia | ||||
| Acura Pharmaceuticals | Formerly VC-backed | Palatine, IL | ||||
| Cipla | Corporation | Mumbai, India |
Amarin Corporation Patents
Amarin Corporation Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024102429-A1 | Methods of reducing risks of cardiovascular events in subjects with low baseline epa:aa ratio | Inactive | 10-Nov-2022 | ||
| AU-2023213684-A1 | Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment | Pending | 26-Jan-2022 | ||
| EP-4468884-A1 | Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment | Pending | 26-Jan-2022 | ||
| EP-4468884-A4 | Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment | Pending | 26-Jan-2022 | ||
| US-20240165066-A1 | Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment | Pending | 26-Jan-2022 | A23J7/00 |
Amarin Corporation Signals
Amarin Corporation Investments & Acquisitions (4)
Amarin Corporation’s most recent deal was a Merger/Acquisition with Ester Neurosciences for . The deal was made on 01-Dec-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ester Neurosciences | 01-Dec-2007 | Merger/Acquisition | Other Devices and Supplies | ||
| Laxdale | 08-Oct-2004 | Merger/Acquisition | Buildings and Property | ||
| VASCEPA | 01-Jan-2004 | Merger/Acquisition | Pharmaceuticals | ||
| Antares Pharma | 01-Dec-1993 | Early Stage VC | Drug Delivery |
Amarin Corporation ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Amarin Corporation Exits (1)
Amarin Corporation’s most recent exit was on 01-Dec-1993 from Antares Pharma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Antares Pharma | 01-Dec-1993 | Completed |
|
Amarin Corporation Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| VASCEPA | Bedminster Township, NJ |
Amarin Corporation FAQs
-
When was Amarin Corporation founded?
Amarin Corporation was founded in 1989.
-
Where is Amarin Corporation headquartered?
Amarin Corporation is headquartered in Dublin, Ireland.
-
What is the size of Amarin Corporation?
Amarin Corporation has 80 total employees.
-
What industry is Amarin Corporation in?
Amarin Corporation’s primary industry is Drug Discovery.
-
Is Amarin Corporation a private or public company?
Amarin Corporation is a Public company.
-
What is Amarin Corporation’s stock symbol?
The ticker symbol for Amarin Corporation is AMRN.
-
What is the current stock price of Amarin Corporation?
As of 20-Nov-2026 the stock price of Amarin Corporation is $10.55.
-
What is the current market cap of Amarin Corporation?
The current market capitalization of Amarin Corporation is $222M.
-
What is Amarin Corporation’s current revenue?
The trailing twelve month revenue for Amarin Corporation is $176M.
-
Who are Amarin Corporation’s competitors?
Landsteiner Scientific, Elite Pharmaceuticals, Mayne Pharma Group, Acura Pharmaceuticals, and Cipla are some of the 23 competitors of Amarin Corporation.
-
What is Amarin Corporation’s annual earnings per share (EPS)?
Amarin Corporation’s EPS for 12 months was -$0.80.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process